Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We provide the first characterization of a novel signaling adapter,
Nesca
, in neurotrophic signal transduction.
Nesca
contains a RUN domain, a WW domain, a leucine zipper, a carboxyl-terminal SH3 domain, and several proline-rich regions.
Nesca
is highly expressed in the brain, is serine phosphorylated, and mobilizes from the cytoplasm to the nuclear membrane in response to neurotrophin, but not epidermal growth factor, stimulation in a
MEK
-dependent process. Overexpression studies in PC12 cells indicate that
Nesca
facilitates neurotrophin-dependent neurite outgrowth at nonsaturating doses of nerve growth factor (NGF). Similarly, short interfering RNA studies significantly reduce NGF-dependent neuritogenesis in PC12 cells. Mutational analyses demonstrate that the RUN domain is an important structural determinant for the nuclear translocation of
Nesca
and that the nuclear redistribution of
Nesca
is essential to its neurite outgrowth-promoting properties. Collectively, these works provide the first functional characterization of
Nesca
in the context of neurotrophin signaling and suggest that
Nesca
serves a novel, nuclear-dependent role in neurotrophin-dependent neurite outgrowth.
...
PMID:Nesca, a novel adapter, translocates to the nuclear envelope and regulates neurotrophin-induced neurite outgrowth. 1502 33